Literature DB >> 12036430

Recent and ongoing clinical trials for treating colorectal cancer.

Mary F Mulcahy1, Al B Benson.   

Abstract

Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III colon cancer. The role of adjuvant chemotherapy in stage II colon cancer remains an unresolved issue. Recent studies have demonstrated an improved survival with the addition of irinotecan to 5-fluorouracil and leucovorin for the treatment of advanced colorectal cancer. Immunotherapy, molecular targeted therapy and liver-directed therapy, in addition to new chemotherapy combinations, are all being evaluated for the treatment of localised and advanced colorectal cancer. Ongoing and proposed studies are incorporating the identification of genetic and molecular abnormalities, which may provide prognostic information as well as direct treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036430     DOI: 10.1517/13543784.11.6.871

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  2 in total

1.  TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model.

Authors:  Grigore Cernaianu; Sibylle Frank; Katrin Erbstösser; Sandy Leonhardt; Michael Cross; Zoe McIvor; Gabriele Scholz; Temuujin Dansranjavin; Ilhan Celik; Andrea Tannapfel; Christian Wittekind; Ralf-Bodo Troebs; Karin Rothe; Joachim Bennek; Johann Hauss; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2005-06-04       Impact factor: 2.571

Review 2.  Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.

Authors:  Dene Simpson; Christopher Dunn; Monique Curran; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.